Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
enGene Holdings (ENGN)
NASDAQ:ENGN
enGene Holdings (ENGN) Stock Price & Analysis
10 Followers
ENGN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$6.69 - $47.17
Previous Close$13.62
Volume27.00
Average Volume (3M)64.96K
Market Cap
$600.41M
Enterprise Value$519.45M
Total Cash (Recent Filing)$81.52M
Total Debt (Recent Filing)$562.00K
Price to Earnings (P/E)-2.6
Beta-1.37
Next Earnings
Mar 11, 2024EPS Estimate
-$0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.15
Shares Outstanding43,581,331
10 Day Avg. Volume145,847
30 Day Avg. Volume64,957
Standard Deviation0.41
R-Squared0.41
Alpha0.06
Financial Highlights & Ratios
Price to Book (P/B)8.56
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-992.72
Forecast
1Y Price Target
$34.40Price Target Upside152.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
enGene Holdings News
PremiumCompany Announcements
enGene Holdings Shareholders Back Directors and Equity Plan
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentEG-70 is advancing in clinical development for treating BCG-unresponsive non-muscle invasive bladder cancer, signaling potential growth for EnGene's lead product.
Market PotentialWith its ease of use and potential efficacy, EG-70 could become the treatment of choice in a large market, offering a significant advantage over existing therapies.
Upcoming EventsAnticipated interim Phase 2 efficacy data for EG-70 could serve as a key catalyst, potentially enhancing the stock's value upon positive results.
Bears Say
Market AdoptionAggressive pricing and BCG coadministration label pose headwinds to market adoption.
Regulatory ChallengesThe FDA previously cited deficiencies related to the pre-license inspection and required updates to DoR and safety data, indicating potential regulatory challenges.
Safety ConcernsSerious adverse events occurred in 16% of patients treated with Anktiva + BCG, which could raise safety concerns.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ENGN FAQ
What was enGene Holdings’s price range in the past 12 months?
enGene Holdings lowest stock price was $6.69 and its highest was $47.17 in the past 12 months.
What is enGene Holdings’s market cap?
Currently, no data Available
When is enGene Holdings’s upcoming earnings report date?
enGene Holdings’s upcoming earnings report date is Mar 11, 2024 which is 66 days ago.
How were enGene Holdings’s earnings last quarter?
enGene Holdings released its earnings results on Jan 29, 2024. The company reported -$73.933 earnings per share for the quarter, missing the consensus estimate of N/A by -$73.933.
Is enGene Holdings overvalued?
According to Wall Street analysts enGene Holdings’s price is currently Undervalued.
Does enGene Holdings pay dividends?
enGene Holdings does not currently pay dividends.
What is enGene Holdings’s EPS estimate?
enGene Holdings’s EPS estimate is -$0.42.
How many shares outstanding does enGene Holdings have?
enGene Holdings has 44,083,076 shares outstanding.
What happened to enGene Holdings’s price movement after its last earnings report?
enGene Holdings reported an EPS of -$73.933 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.573%.
Which hedge fund is a major shareholder of enGene Holdings?
Among the largest hedge funds holding enGene Holdings’s share is Omega Fund Management, LLC. It holds enGene Holdings’s shares valued at 18M.
---
enGene Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$34.40 (152.57% Upside)
$34.40 (152.57% Upside)
Blogger Sentiment
Bullish
ENGN Sentiment 100%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Decreased
By 54.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $740.9K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
28.79%
12-Months-Change
Fundamentals
Return on Equity
-119.64%
Trailing 12-Months
Asset Growth
-30.05%
Trailing 12-Months
Company Description
enGene Holdings
Forbion European Acquisition Corp is a blank check company.
---
ENGN Stock 12 Month Forecast
Average Price Target
$34.40
▲(152.57% Upside)
Technical Analysis
Best Analysts Covering ENGN
1 Year
1 Year Success Rate
0/4 ratings generated profit
1 Year Average Return
-14.50%
reiterated a buy rating 11 days ago
Copying Mani Foroohar's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -14.50% per trade.
---